Yi-Hsuan Chiang

Yi-Hsuan Chiang

Auto-generated profile, based on publicly available information

Yi-Hsuan Chiang

University of Lausanne

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Nature Aging
Verified
Journal Article
Closed access
PDF file
MGMukul Girotra
Mukul Girotra
YCYi-Hsuan Chiang
Yi-Hsuan Chiang
MCMelanie Charmoy
Melanie Charmoy
PGPierpaolo Ginefra
Pierpaolo Ginefra
HHHelen Carrasco Hope
Helen Carrasco Hope
NVNicola Vannini
Nicola Vannini

3 May 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
PGPierpaolo Ginefra
Pierpaolo Ginefra
HHHelen Carrasco Hope
Helen Carrasco Hope
YCYi-Hsuan Chiang
Yi-Hsuan Chiang
SNSophie Nutten
Sophie Nutten
SBStephanie Blum
Stephanie Blum
NVNicola Vannini
Nicola Vannini
Naïve T cells are key players in cancer immunosurveillance, even though their function declines during tumor progression. Thus, interventions capable of sustaining the quality and function of naïve T cells are needed to improve cancer immunoprevention. In this context, we studied the capacity of Urolithin-A (UroA), a potent mitophagy inducer, to enhance T cell–mediated cancer immunosurveillance. We discovered that UroA improved the cancer immune response by activating the transcription factor FOXO1 in CD8+ T cell. Sustained FOXO1 activation promoted the expression of the adhesion molecule L-selectin (CD62L) resulting in the expansion of the naïve T cells population. We found that UroA reduces FOXO1 phosphorylation favoring its nuclear localization and transcriptional activity. Overall, our findings determine FOXO1 as a novel molecular target of UroA in CD8+ T cells and indicate UroA as promising immunomodulator to improve cancer immunosurveillance. Significance: Urolithin-A, a potent mitophagy inducer, emerges as a promising tool to enhance cancer immunosurveillance by activating the FOXO1 transcription factor in CD8+ T cells. This activation promotes the expansion of naïve T cells, offering a novel avenue for improving cancer immune response and highlighting UroA as a potential immunomodulator for bolstering our body's defenses against cancer.

4 October 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
YXYingxi Xu
Yingxi Xu
YCYi-Hsuan Chiang
Yi-Hsuan Chiang
PHPing-Chih Ho
Ping-Chih Ho
NVNicola Vannini
Nicola Vannini
Hematopoietic stem cells (HSC) and T cells are intimately related, lineage-dependent cell populations that are extensively used as therapeutic products for the treatment of hematologic malignancies and certain types of solid tumors. These cellular therapies can be life-saving treatments; however, their efficacies are often limited by factors influencing their activity and cellular properties. Among these factors is mitochondrial metabolism, which influences the function and fate commitment of both HSCs and T cells. Mitochondria, besides being the “cellular powerhouse,” provide metabolic intermediates that are used as substrates for epigenetic modifications and chromatin remodeling, thus, driving cell fate decisions during differentiation. Moreover, mitochondrial fitness and mitochondrial quality control mechanisms are closely related to cellular function, and impairment of these mitochondrial properties associates with cellular dysfunction due to factors such as T-cell exhaustion and aging. Here, we give an overview of the role of mitochondria in shaping the behavior of these lineage-related cell populations. Moreover, we discuss the potential of novel mitochondria-targeting strategies for enhancing HSC- and T cell–based cancer immunotherapies and highlight how design and application of such approaches requires consideration of the metabolic similarities and differences between HSCs and T cells. See related article on p. 1302.

1 July 2025 in Physiology
Verified
Journal Article
Closed access
YCYi-Hsuan Chiang
Yi-Hsuan Chiang
SEStephan Emmrich
Stephan Emmrich
NVNicola Vannini
Nicola Vannini
Aging is a multifaceted process associated with a functional decline in cellular function over time, affecting all lifeforms. During the aging process, metabolism, a fundamental hallmark of life ( 1 ), is profoundly altered. In the context of hematopoiesis, the proper function of hematopoietic stem cells, at the apex of the blood system, is tightly linked to their energy metabolism, which in turn shapes hematopoietic output. Here, we review the latest developments in our understanding of the metabolic states and changes in aged hematopoietic stem cells, molecular players and pathways involved in aged hematopoietic stem cell metabolism, the consequences of perturbed metabolism on clonal hematopoiesis and leukemogenesis, and pharmacologic/genetic strategies to reverse or rejuvenate altered metabolic phenotypes.

3 May 2024
Verified
Other
Open access
PGPierpaolo Ginefra
Pierpaolo Ginefra
HHHelen Carrasco Hope
Helen Carrasco Hope
YCYi-Hsuan Chiang
Yi-Hsuan Chiang
SNSophie Nutten
Sophie Nutten
SBStephanie Blum
Stephanie Blum
NVNicola Vannini
Nicola Vannini
UroA improve functionality of T cells in vitro

3 May 2024
Verified
Other
Open access
PGPierpaolo Ginefra
Pierpaolo Ginefra
HHHelen Carrasco Hope
Helen Carrasco Hope
YCYi-Hsuan Chiang
Yi-Hsuan Chiang
SNSophie Nutten
Sophie Nutten
SBStephanie Blum
Stephanie Blum
NVNicola Vannini
Nicola Vannini
UroA-induced FOXO1 transcriptional activity is mitophagy independent. A, Quantification of CD62 L expression level in CD8+ T treated with UroA (5 µmol/L) and in presence of FOXO1 inhibitor (Foxo inh 50 nmol/L) for 48 hours in vitro. Values are expressed as fold change compare with control condition. B, Schematic representation of FOXO1 inhibition in vivo analyzed in C. C, Quantification of naïve CD8+ T population isolated from mice fed with UroA diet and treated with Foxo inh. Values are expressed as fold change compare with control condition (left). Quantification of CD62 L expression level in CD8+ T isolated from mice fed with UroA diet and treated with Foxo inh (right) for 48 hours in vitro. D, Expression level of PGC1α in CD8+ T treated with UroA (5 µmol/L) for 48 hours in vitro. E, Quantification of Mito-QC CD8+ T cells engaging mitophagy under indicated condition in vitro for 24 hours (UroA 5 µmol/L, Foxo inh 50 nmol/L). Quantification of mCherry/GFP ratio from E (right). F, Expression level of PGC1α in CD8+ T cells cultured in presence of Foxo inh (50 nmol/L) or mitophagy blocker (mDivi 10 µmol/L) for 48 hours in vitro. Data are mean ± SEM. Each dot represents a biological replicate. In A, sample size n = 9. In C, sample size n = 8. In D, sample size n = 6. In E, sample size n = 7. In F, sample size n = 3. Data were analyzed by two-sided Student t or ANOVA test followed by multiple comparison test (*, P < 0.05; **, P < 0.01; ****, P < 0.0001). Representative results of at least two independent experiments or two pooled experiments.